Telix Pharmaceuticals Limited Stock Current Valuation
| TLPPF Stock | USD 14.56 0.50 3.56% |
Valuation analysis of Telix Pharmaceuticals helps investors to measure Telix Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Telix Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Telix Pharmaceuticals is based on 3 months time horizon. Increasing Telix Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Telix pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Telix Pharmaceuticals Limited. Since Telix Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Telix Pink Sheet. However, Telix Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 14.56 | Real 11.63 | Hype 14.06 |
The real value of Telix Pink Sheet, also known as its intrinsic value, is the underlying worth of Telix Pharmaceuticals Company, which is reflected in its stock price. It is based on Telix Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Telix Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Telix Pharmaceuticals Limited helps investors to forecast how Telix pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Telix Pharmaceuticals more accurately as focusing exclusively on Telix Pharmaceuticals' fundamentals will not take into account other important factors: Telix Pharmaceuticals Limited Company Current Valuation Analysis
Telix Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Telix Pharmaceuticals Current Valuation | 1.39 B |
Most of Telix Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Telix Pharmaceuticals Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Telix Pharmaceuticals Limited has a Current Valuation of 1.39 B. This is 90.36% lower than that of the Healthcare sector and 70.18% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 91.67% higher than that of the company.
Telix Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Telix Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Telix Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Telix Pharmaceuticals by comparing valuation metrics of similar companies.Telix Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Telix Fundamentals
| Return On Equity | -1.55 | |||
| Return On Asset | -0.41 | |||
| Operating Margin | (3.95) % | |||
| Current Valuation | 1.39 B | |||
| Shares Outstanding | 317.02 M | |||
| Shares Owned By Insiders | 27.60 % | |||
| Shares Owned By Institutions | 13.59 % | |||
| Price To Book | 21.16 X | |||
| Price To Sales | 52.21 X | |||
| Revenue | 4.9 M | |||
| Gross Profit | 5.05 M | |||
| EBITDA | (70.07 M) | |||
| Net Income | (80.51 M) | |||
| Cash And Equivalents | 122.61 M | |||
| Cash Per Share | 0.39 X | |||
| Total Debt | 2.57 M | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 3.21 X | |||
| Book Value Per Share | 0.34 X | |||
| Cash Flow From Operations | (59.33 M) | |||
| Earnings Per Share | (0.20) X | |||
| Number Of Employees | 11 | |||
| Beta | 2.31 | |||
| Market Capitalization | 1.44 B | |||
| Total Asset | 109.81 M | |||
| Net Asset | 109.81 M |
About Telix Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Telix Pharmaceuticals Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telix Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telix Pharmaceuticals Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Telix Pink Sheet
When determining whether Telix Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Telix Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Telix Pharmaceuticals Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Telix Pharmaceuticals Limited Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telix Pharmaceuticals Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.